Category Archives: drug design
An emergency medicine journal has retracted a letter to the editor, saying it didn’t include the author’s relevant commercial interest—which the author says he tried to disclose when he submitted the paper. The author, Guy Weinberg, told Retraction Watch he had noted his conflict of interest when he submitted the letter last March, but said […]
The post Journal retracts letter for missing disclosure author says he tried to submit appeared first on Retraction Watch.
The Lancet has retracted a journalist-written piece about a controversial drug used off-label to induce abortions, and replaced it with a corrected version. In the retraction notice, the journal said it “removed the information that we believe to be inaccurate.” The article, first published Oct. 28, 2017, highlights Pfizer’s decision to withdraw the drug, misoprostol, […]
The post Lancet retracts and replaces news story about controversial abortion drug appeared first on Retraction Watch.
Earlier this year, a raging controversy regarding a new drug spilled into the pages of a leading medical journal: the head of the U.S. Food and Drug Administration and another official publicly called for the retraction or correction of a peer-reviewed article about the drug. They didn’t get their wish. Now, documents released by the […]
The post Released FDA docs reveal details of agency’s (failed) attempt to retract paper appeared first on Retraction Watch.
On June 19, 2017, the U.S. Office of Research Integrity published its first misconduct finding of the year. The ORI reported that Brandi M. Baughman — a former research training awardee at the National Institute of Environmental and Health Sciences (NIEHS) — had “falsified and/or fabricated data” in 11 figures in a 2016 paper published in PLOS […]
The post PLOS ONE retracts paper after researcher admits to fabricating data appeared first on Retraction Watch.